 |
(3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (2R,3R)-2,3-dihydroxybutanedioate |
|---|---|
| Trade Name | |
| Orphan Indication | Still’s disease |
| USA Market Approval | USA |
| USA Designation Date | 2015-09-18 00:00:00 |
| Sponsor | AbbVie, Inc.;1 North Waukegan Road;North Chicago, Illinois, 60064 |
